Novartis India

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE234A01025
NSEID: NOVARTIND
BSEID: 500672
View on NSE | View on BSE

INR

1,609.70

-25.2 (-1.54%)

BSENSE

Aug 06, 03:30 PM

BSE+NSE Vol: 29.0 k

{
  "main_header": {
    "sid": 333626,
    "name": "Novartis India",
    "stock_name": "Novartis India",
    "full_name": "Novartis India Ltd",
    "name_url": "stocks-analysis/novartis-india",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,609.70",
    "chg": -25.2,
    "chgp": "-1.54%",
    "dir": -1,
    "prev_price": "1,634.90",
    "mcapval": "4,096.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 500672,
    "symbol": "NOVARTIND",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE234A01025",
    "curr_date": "Aug 06, 03:30 PM",
    "curr_time": "17:52 PM",
    "last_traded_at": "Aug 06, 03:30 PM IST",
    "bse_nse_vol": "29.0 k",
    "exc_status": "Active",
    "traded_date": "Aug 06, 2026",
    "traded_date_str": "2026 08 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/novartis-india-333626-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Novartis India Ltd is Rated Buy by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/novartis-india-ltd-is-rated-buy-by-marketsmojo-4124216",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NovartisIndiaLt_mojoScore_4124216.png",
        "date": "2026-07-28 10:10:03",
        "description": "Novartis India Ltd is rated Buy by MarketsMOJO, with this rating last updated on 23 July 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 28 July 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Novartis India Gains 4.90%: 5 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novartis-india-gains-490-5-key-factors-driving-the-weeks-momentum-4121384",
        "imagepath": "",
        "date": "2026-07-26 14:01:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>20 Jul:</strong> Stock surges 6.51% on strong volume</p>\n                    <p><strong>21 Jul:</strong> Continued gains with 1.60% rise and steady delivery volumes</p>\n                    <p><strong>22 Jul:</strong> Minor dip amid broader market weakness</p>\n                    <p><strong>23 Jul:</strong> New 52-week and all-time high reached intraday at Rs.1,777.5</p>\n                    <p><strong>24 Jul:</strong> Week closes at Rs.1,647.25, down 1.30% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,672.55</div></div>\n                    ..."
      },
      {
        "title": "Are Novartis India Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-novartis-india-ltd-latest-results-good-or-bad-4119772",
        "imagepath": "",
        "date": "2026-07-24 19:17:06",
        "description": "Novartis India Ltd's latest financial results for Q1 FY27 demonstrate a notable operational performance, characterized by significant growth in both revenue and net profit. The company reported net sales of ₹103.81 crores, reflecting an 18.57% increase year-on-year, compared to a decline in the same quarter the previous year. This marks a strong recovery from prior periods, indicating a robust demand across its product offerings.\n\nNet profit for the quarter stood at ₹32.21 crores, which is a 16.62% increase year-on-year, showcasing the company's ability to enhance profitability alongside revenue growth. The operating margin also saw a substantial improvement, reaching 33.63%, which is the highest level in at least seven quarters, driven by effective cost management and a favorable product mix.\n\nThe quarter's results indicate a decisive turnaround from the previous quarter, where growth was more subdued. The..."
      },
      {
        "title": "Novartis India Ltd Reports Strong Quarterly Turnaround with Robust Revenue and Margin Expansion",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novartis-india-ltd-reports-strong-quarterly-turnaround-with-robust-revenue-and-margin-expansion-4118419",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NovartisIndiaLt_fintrenddot_4118419.png",
        "date": "2026-07-24 08:00:09",
        "description": "Novartis India Ltd has demonstrated a remarkable financial turnaround in the quarter ended June 2026, shifting from a negative trend to a positive trajectory with record-breaking revenue and profit metrics. This resurgence is underscored by significant margin expansion and operational efficiency gains, positioning the small-cap pharmaceutical player favourably against its historical performance and broader market benchmarks."
      },
      {
        "title": "Novartis India Q1 FY27: Strong Profit Surge Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/novartis-india-q1-fy27-strong-profit-surge-masks-valuation-concerns-4118258",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NovartisIndia_quaterlyResult_4118258.png",
        "date": "2026-07-23 18:15:50",
        "description": "Novartis India Ltd. (NSE: NOVARTIND), the domestic subsidiary of Swiss pharmaceutical giant Novartis AG, posted a robust performance in Q1 FY27 (June 2026 quarter), with net profit surging 27.56% quarter-on-quarter to ₹32.21 crores, marking its highest quarterly profit in recent periods. However, the stock retreated 1.77% following the results announcement, as investors grappled with premium valuation concerns despite the strong operational performance."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1777.5",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novartis-india-ltd-hits-new-52-week-high-at-rs17775-4117983",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NovartisIndiaLt_priceRelatedfactors_4117983.png",
        "date": "2026-07-23 13:15:23",
        "description": ""
      },
      {
        "title": "Novartis India Ltd Hits All-Time High of Rs 1,745 as Momentum Builds Across Timeframes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novartis-india-ltd-stock-hits-all-time-high-on-23-jul-2026-4117934",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NovartisIndiaLt_priceRelatedfactors_4117934.png",
        "date": "2026-07-23 12:56:50",
        "description": "Extending its remarkable rally, Novartis India Ltd touched a fresh all-time high of Rs 1,745 on 23 Jul 2026, marking a significant milestone in its recent price trajectory."
      },
      {
        "title": "Novartis India Ltd Upgrades Quality Grade Amid Strong Financial Fundamentals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novartis-india-ltd-upgrades-quality-grade-amid-strong-financial-fundamentals-4116839",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NovartisIndiaLt_qualitydot_4116839.png",
        "date": "2026-07-23 08:00:07",
        "description": "Novartis India Ltd has seen its quality grade upgraded from average to good, reflecting notable improvements in its business fundamentals. Despite a modest decline in sales growth over five years, the company’s robust profitability, conservative debt levels, and strong returns on capital have underpinned this positive reassessment, positioning it favourably within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Novartis India Ltd Gains 5.33%: 5 Key Factors Driving the Week’s Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/novartis-india-ltd-gains-533-5-key-factors-driving-the-weeks-momentum-4107801",
        "imagepath": "",
        "date": "2026-07-19 09:00:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>13 Jul:</strong> New 52-week high at Rs.1,629.90 and all-time intraday peak</p>\n                    <p><strong>14 Jul:</strong> Stock hits new 52-week and all-time high at Rs.1,711.05</p>\n                    <p><strong>15 Jul:</strong> Price correction with a 4.32% decline amid lower volumes</p>\n                    <p><strong>16 Jul:</strong> Recovery rally of 3.56% supported by technical indicators</p>\n                    <p><strong>17 Jul:</strong> Week closes at Rs.1,570.30, down 2.06% on the day but up for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"st..."
      }
    ],
    "total": 287,
    "sid": "333626",
    "stock_news_url": "https://www.marketsmojo.com/news/novartis-india-333626"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Novartis India Ltd has declared <strong>500%</strong> dividend, ex-date: 23 Jul 25",
          "dt": "2025-07-23",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Novartis India Ltd is Rated Buy by MarketsMOJO

2026-07-28 10:10:03

Novartis India Ltd is rated Buy by MarketsMOJO, with this rating last updated on 23 July 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 28 July 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Read full news article

Novartis India Gains 4.90%: 5 Key Factors Driving the Week’s Momentum

2026-07-26 14:01:07

Key Events This Week

20 Jul: Stock surges 6.51% on strong volume

21 Jul: Continued gains with 1.60% rise and steady delivery volumes

22 Jul: Minor dip amid broader market weakness

23 Jul: New 52-week and all-time high reached intraday at Rs.1,777.5

24 Jul: Week closes at Rs.1,647.25, down 1.30% on the day

Week Open

Rs.1,672.55

...

Read full news article

Are Novartis India Ltd latest results good or bad?

2026-07-24 19:17:06

Novartis India Ltd's latest financial results for Q1 FY27 demonstrate a notable operational performance, characterized by significant growth in both revenue and net profit. The company reported net sales of ₹103.81 crores, reflecting an 18.57% increase year-on-year, compared to a decline in the same quarter the previous year. This marks a strong recovery from prior periods, indicating a robust demand across its product offerings. Net profit for the quarter stood at ₹32.21 crores, which is a 16.62% increase year-on-year, showcasing the company's ability to enhance profitability alongside revenue growth. The operating margin also saw a substantial improvement, reaching 33.63%, which is the highest level in at least seven quarters, driven by effective cost management and a favorable product mix. The quarter's results indicate a decisive turnaround from the previous quarter, where growth was more subdued. The...

Read full news article

Novartis India Ltd Reports Strong Quarterly Turnaround with Robust Revenue and Margin Expansion

2026-07-24 08:00:09

Novartis India Ltd has demonstrated a remarkable financial turnaround in the quarter ended June 2026, shifting from a negative trend to a positive trajectory with record-breaking revenue and profit metrics. This resurgence is underscored by significant margin expansion and operational efficiency gains, positioning the small-cap pharmaceutical player favourably against its historical performance and broader market benchmarks.

Read full news article

Novartis India Q1 FY27: Strong Profit Surge Masks Valuation Concerns

2026-07-23 18:15:50

Novartis India Ltd. (NSE: NOVARTIND), the domestic subsidiary of Swiss pharmaceutical giant Novartis AG, posted a robust performance in Q1 FY27 (June 2026 quarter), with net profit surging 27.56% quarter-on-quarter to ₹32.21 crores, marking its highest quarterly profit in recent periods. However, the stock retreated 1.77% following the results announcement, as investors grappled with premium valuation concerns despite the strong operational performance.

Read full news article

Broad-Based Technical Strength Lifts Novartis India Ltd to 52-Week High of Rs 1777.5

2026-07-23 13:15:23

Read full news article

Novartis India Ltd Hits All-Time High of Rs 1,745 as Momentum Builds Across Timeframes

2026-07-23 12:56:50

Extending its remarkable rally, Novartis India Ltd touched a fresh all-time high of Rs 1,745 on 23 Jul 2026, marking a significant milestone in its recent price trajectory.

Read full news article

Novartis India Ltd Upgrades Quality Grade Amid Strong Financial Fundamentals

2026-07-23 08:00:07

Novartis India Ltd has seen its quality grade upgraded from average to good, reflecting notable improvements in its business fundamentals. Despite a modest decline in sales growth over five years, the company’s robust profitability, conservative debt levels, and strong returns on capital have underpinned this positive reassessment, positioning it favourably within the Pharmaceuticals & Biotechnology sector.